TQC2731 clinical trials
How each study uses TQC2731 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the TQC2731 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. (3) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (3)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 1 in phase 3
Studies that test TQC2731, phase 3 first.
- Mar 2027Clinical Trial of TQC2731 Injection in Patients With Chronic Sinusitis and Nasal PolypsPhase 3 · Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
- Dec 2026A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseasePhase 2 · Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Studies
Open first, then newest update. How each study uses TQC2731 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- TQC2731 Clinical Trial for the Treatment of Severe Asthma With InjectionRecruitingPhase 3Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.NCT06829784Written as TQC2731 injection
- Clinical Trial of TQC2731 Injection in Patients With Chronic Sinusitis and Nasal PolypsActive, not recruitingPhase 3Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.NCT07107256Written as TQC2731 injection
- A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseaseActive, not recruitingPhase 2Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.NCT06707883Written as TQC2731 injection
- Evaluate the Efficacy and Safety of TQC2731 Injection in Patients With Severe Asthma.CompletedPhase 2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05472324Written as TQC2731 injection
- A Clinical Study of TQC2731 Injection in the Treatment of Chronic Rhinosinusitis With Nasal PolypsCompletedPhase 2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06036927Written as TQC2731 injection
- Phase I Clinical Trial of TQC2731 InjectionStatus unknownPhase 1Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT04923607Written as TQC2731